Filing Details
- Accession Number:
- 0001144204-16-089007
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-03-18 21:33:26
- Reporting Period:
- 2016-03-16
- Filing Date:
- 2016-03-18
- Accepted Time:
- 2016-03-18 21:33:26
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1133869 | Capricor Therapeutics Inc. | CAPR | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1563615 | Leland Gershell | C/O Capricor Therapeutics, Inc. 8840 Wilshire Blvd., 2Nd Floor Beverly Hills CA 90211 | Chief Financial Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2016-03-16 | 2,100 | $2.40 | 2,100 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Warrants (Right to Buy) | Acquisiton | 2016-03-16 | 1,050 | $0.13 | 1,050 | $4.50 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
1,050 | 2016-09-17 | 2019-03-16 | No | 4 | P | Direct |
Footnotes
- The Reporting Person entered into a Subscription Agreement with Capricor Therapeutics, Inc. (the "Issuer") pursuant to which the Reporting Person, on March 16, 2016, purchased (i) 2,100 shares of the Issuer's common stock at a purchase price of $2.40 per share, and (ii) warrants to purchase up to an aggregate of 1,050 shares of the Issuer's common stock at a purchase price of $0.125 per share issuable upon exercise of the warrants, for an aggregate purchase price of approximately $5,171.